Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses

Tomonori Yaguchi, Asuka Kobayashi, Takashi Inozume, Kenji Morii, Haruna Nagumo, Hiroshi Nishio, Takashi Iwata, Yuyo Ka, Ikumi Katano, Ryoji Ito, Mamoru Ito, Yutaka Kawakami

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Immunodeficient mice engrafted with human peripheral blood cells are promising tools for in vivo analysis of human patient individual immune responses. However, when human peripheral blood mononuclear cells (PBMCs) are transferred into NOG (NOD/Shi-scid, IL-2rgnull) mice, severe graft versus host disease (GVHD) hinders long term detailed analysis. Administration of human PBMCs into newly developed murine MHC class I- and class II-deficient NOG (NOG-dKO; NOG- Iab, B2m-double-knockout) mice showed sufficient engraftment of human immune cells with little sign of GVHD. Immunization with influenza vaccine resulted in an increase in influenza-specific human IgG Ab, indicating induction of antigen-specific B cells in the NOG-dKO mice. Immunization with human dendritic cells pulsed with HLA-A2 restricted cytomegalovirus peptide induced specific cytotoxic T cells, indicating the induction of antigen-specific T cells in the NOG-dKO mice. Adoptive cell therapies (ACTs) using melanoma antigen recognized by T cells (MART-1)-specific TCR-transduced activated T cells showed strong tumor growth inhibition in NOG-dKO mice without any sign of GVHD accompanied by preferential expansion of the transferred MART-1-specific T cells. ACTs using cultured human melanoma infiltrating T cells also showed anti-tumor effects against autologous melanoma cells in NOG-dKO mice, in which changes in human cancer phenotypes by immune intervention, such as increased CD271 expression, could be evaluated. Therefore, NOG-dKO mice are useful tools for more detailed analysis of both the induction and effector phases of T-cell and B-cell responses for a longer period than regular NOG mice.

Original languageEnglish
Pages (from-to)953-962
Number of pages10
JournalCellular and Molecular Immunology
Volume15
Issue number11
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Blood Cells
T-Lymphocytes
Graft vs Host Disease
Cell- and Tissue-Based Therapy
Melanoma
Immunization
B-Lymphocytes
MART-1 Antigen
HLA-A2 Antigen
Antigens
Neoplasms
Influenza Vaccines
Cytomegalovirus
Knockout Mice
Dendritic Cells
Human Influenza
Immunoglobulin G
Phenotype
Peptides
Growth

Keywords

  • adoptive cell therapy
  • humanized mouse
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. / Yaguchi, Tomonori; Kobayashi, Asuka; Inozume, Takashi; Morii, Kenji; Nagumo, Haruna; Nishio, Hiroshi; Iwata, Takashi; Ka, Yuyo; Katano, Ikumi; Ito, Ryoji; Ito, Mamoru; Kawakami, Yutaka.

In: Cellular and Molecular Immunology, Vol. 15, No. 11, 01.11.2018, p. 953-962.

Research output: Contribution to journalArticle

Yaguchi, T, Kobayashi, A, Inozume, T, Morii, K, Nagumo, H, Nishio, H, Iwata, T, Ka, Y, Katano, I, Ito, R, Ito, M & Kawakami, Y 2018, 'Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses', Cellular and Molecular Immunology, vol. 15, no. 11, pp. 953-962. https://doi.org/10.1038/cmi.2017.106
Yaguchi, Tomonori ; Kobayashi, Asuka ; Inozume, Takashi ; Morii, Kenji ; Nagumo, Haruna ; Nishio, Hiroshi ; Iwata, Takashi ; Ka, Yuyo ; Katano, Ikumi ; Ito, Ryoji ; Ito, Mamoru ; Kawakami, Yutaka. / Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. In: Cellular and Molecular Immunology. 2018 ; Vol. 15, No. 11. pp. 953-962.
@article{a421beafe8de4726bd05d96aa5ad64f9,
title = "Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses",
abstract = "Immunodeficient mice engrafted with human peripheral blood cells are promising tools for in vivo analysis of human patient individual immune responses. However, when human peripheral blood mononuclear cells (PBMCs) are transferred into NOG (NOD/Shi-scid, IL-2rgnull) mice, severe graft versus host disease (GVHD) hinders long term detailed analysis. Administration of human PBMCs into newly developed murine MHC class I- and class II-deficient NOG (NOG-dKO; NOG- Iab, B2m-double-knockout) mice showed sufficient engraftment of human immune cells with little sign of GVHD. Immunization with influenza vaccine resulted in an increase in influenza-specific human IgG Ab, indicating induction of antigen-specific B cells in the NOG-dKO mice. Immunization with human dendritic cells pulsed with HLA-A2 restricted cytomegalovirus peptide induced specific cytotoxic T cells, indicating the induction of antigen-specific T cells in the NOG-dKO mice. Adoptive cell therapies (ACTs) using melanoma antigen recognized by T cells (MART-1)-specific TCR-transduced activated T cells showed strong tumor growth inhibition in NOG-dKO mice without any sign of GVHD accompanied by preferential expansion of the transferred MART-1-specific T cells. ACTs using cultured human melanoma infiltrating T cells also showed anti-tumor effects against autologous melanoma cells in NOG-dKO mice, in which changes in human cancer phenotypes by immune intervention, such as increased CD271 expression, could be evaluated. Therefore, NOG-dKO mice are useful tools for more detailed analysis of both the induction and effector phases of T-cell and B-cell responses for a longer period than regular NOG mice.",
keywords = "adoptive cell therapy, humanized mouse, vaccine",
author = "Tomonori Yaguchi and Asuka Kobayashi and Takashi Inozume and Kenji Morii and Haruna Nagumo and Hiroshi Nishio and Takashi Iwata and Yuyo Ka and Ikumi Katano and Ryoji Ito and Mamoru Ito and Yutaka Kawakami",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/cmi.2017.106",
language = "English",
volume = "15",
pages = "953--962",
journal = "Cellular and Molecular Immunology",
issn = "1672-7681",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses

AU - Yaguchi, Tomonori

AU - Kobayashi, Asuka

AU - Inozume, Takashi

AU - Morii, Kenji

AU - Nagumo, Haruna

AU - Nishio, Hiroshi

AU - Iwata, Takashi

AU - Ka, Yuyo

AU - Katano, Ikumi

AU - Ito, Ryoji

AU - Ito, Mamoru

AU - Kawakami, Yutaka

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Immunodeficient mice engrafted with human peripheral blood cells are promising tools for in vivo analysis of human patient individual immune responses. However, when human peripheral blood mononuclear cells (PBMCs) are transferred into NOG (NOD/Shi-scid, IL-2rgnull) mice, severe graft versus host disease (GVHD) hinders long term detailed analysis. Administration of human PBMCs into newly developed murine MHC class I- and class II-deficient NOG (NOG-dKO; NOG- Iab, B2m-double-knockout) mice showed sufficient engraftment of human immune cells with little sign of GVHD. Immunization with influenza vaccine resulted in an increase in influenza-specific human IgG Ab, indicating induction of antigen-specific B cells in the NOG-dKO mice. Immunization with human dendritic cells pulsed with HLA-A2 restricted cytomegalovirus peptide induced specific cytotoxic T cells, indicating the induction of antigen-specific T cells in the NOG-dKO mice. Adoptive cell therapies (ACTs) using melanoma antigen recognized by T cells (MART-1)-specific TCR-transduced activated T cells showed strong tumor growth inhibition in NOG-dKO mice without any sign of GVHD accompanied by preferential expansion of the transferred MART-1-specific T cells. ACTs using cultured human melanoma infiltrating T cells also showed anti-tumor effects against autologous melanoma cells in NOG-dKO mice, in which changes in human cancer phenotypes by immune intervention, such as increased CD271 expression, could be evaluated. Therefore, NOG-dKO mice are useful tools for more detailed analysis of both the induction and effector phases of T-cell and B-cell responses for a longer period than regular NOG mice.

AB - Immunodeficient mice engrafted with human peripheral blood cells are promising tools for in vivo analysis of human patient individual immune responses. However, when human peripheral blood mononuclear cells (PBMCs) are transferred into NOG (NOD/Shi-scid, IL-2rgnull) mice, severe graft versus host disease (GVHD) hinders long term detailed analysis. Administration of human PBMCs into newly developed murine MHC class I- and class II-deficient NOG (NOG-dKO; NOG- Iab, B2m-double-knockout) mice showed sufficient engraftment of human immune cells with little sign of GVHD. Immunization with influenza vaccine resulted in an increase in influenza-specific human IgG Ab, indicating induction of antigen-specific B cells in the NOG-dKO mice. Immunization with human dendritic cells pulsed with HLA-A2 restricted cytomegalovirus peptide induced specific cytotoxic T cells, indicating the induction of antigen-specific T cells in the NOG-dKO mice. Adoptive cell therapies (ACTs) using melanoma antigen recognized by T cells (MART-1)-specific TCR-transduced activated T cells showed strong tumor growth inhibition in NOG-dKO mice without any sign of GVHD accompanied by preferential expansion of the transferred MART-1-specific T cells. ACTs using cultured human melanoma infiltrating T cells also showed anti-tumor effects against autologous melanoma cells in NOG-dKO mice, in which changes in human cancer phenotypes by immune intervention, such as increased CD271 expression, could be evaluated. Therefore, NOG-dKO mice are useful tools for more detailed analysis of both the induction and effector phases of T-cell and B-cell responses for a longer period than regular NOG mice.

KW - adoptive cell therapy

KW - humanized mouse

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85051644647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051644647&partnerID=8YFLogxK

U2 - 10.1038/cmi.2017.106

DO - 10.1038/cmi.2017.106

M3 - Article

VL - 15

SP - 953

EP - 962

JO - Cellular and Molecular Immunology

JF - Cellular and Molecular Immunology

SN - 1672-7681

IS - 11

ER -